CHINARES PHARMA (03320) leads the establishment of a 500 million fund, focusing on synthetic biology and innovative drug fields.

CHINARES PHARMA(03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), China Resources Double-Crane Pharmaceutical (as the limited partner), and CHINARES PHARMA Investments (as the limited partner) (each as subsidiaries of the company) and other partners have entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will mainly focus on investing in high-growth enterprises in the field of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total investment amount of RMB 123 million, accounting for approximately 24.6% of the total committed investment amount of the fund. The fund will not be accounted for as subsidiaries of the company after its establishment. Shenzhen China Resources Capital will be appointed as the fund manager. Synthetic biology is one of the strategic development directions of the group. Through the establishment of the fund, the group aims to build a platform for industrializing synthetic biology in Hohhot, optimizing the group's strategic layout in related key areas. In addition, leveraging the synergies of Hohhot's industrial development, the group expects the fund to achieve goals such as enriching investment channels in the synthetic biology industry, promoting innovation incubation, accelerating product technology cooperation, and obtaining commercial product rights. After the establishment of the fund, the fund will be accounted for as equity investments in the company's comprehensive financial statements.